Tag Archive for: Investment

The financing was secured from life sciences investment company Abingworth and will help Gilead run “select clinical studies” of Trodelvy.

At yesterday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.

Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost.

In an interview with Med Ad News, Leo Tarkovsky, chief commercial officer at Fingerpaint Group discusses the transformation in what clients want and need with respect to their partners, along with the evolving expectations of healthcare companies.

A survey of 141 healthcare executives by MD Revolution showed that C-suites are expanding their budgets to establish programs that increase patient and clinician satisfaction, improve outcomes, reduce overall expenses, and unlock new revenue.

According to the announcement, the firm’s mission is to create and build companies developing innovative treatments that could “cure or transform the clinical management” of life-threatening diseases.

Several experts on a panel Wednesday at JPM’s Biotech Showcase expressed positive attitudes for the coming year on the investment side, with the industry showing “signs of life”.

“We are in a golden-era of innovation in the life sciences, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” Amit Sinha, head of life sciences investing at Goldman Sachs Asset Management, said in a statement.  

To come up with this list, BioSpace identified companies that launched between September 2022 and September 2023 with Series A funding. They were then assessed using several different criteria including finance, partnerships, pipeline, growth potential and innovation.

Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.